Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1372 TriTCE Co-Stim: a novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the therapeutic window for treatment of poorly infiltrated tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
